{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:46Z","timestamp":1792511926441,"version":"4.5.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s15010-025-02657-y","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:10:00Z","timestamp":1760692200000},"page":"25-39","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiviral strategies against H5N1: current options and emerging therapeutics"],"prefix":"10.1007","volume":"54","author":[{"given":"Cleo","family":"Anastassopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios-Periklis","family":"Panagiotopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Ranellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Mariolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2657_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/v16030374","volume":"16","author":"K Zuo","year":"2024","unstructured":"Zuo K, Gao W, Wu Z, et al. Evolution of virology: science history through milestones and technological advancements. Viruses. 2024;16:374. https:\/\/doi.org\/10.3390\/v16030374","journal-title":"Viruses"},{"key":"2657_CR2","doi-asserted-by":"publisher","first-page":"a038695","DOI":"10.1101\/cshperspect.a038695","volume":"10","author":"JK Taubenberger","year":"2020","unstructured":"Taubenberger JK, Morens DM. The 1918 influenza pandemic and its legacy. Cold Spring Harb Perspect Med. 2020;10:a038695. https:\/\/doi.org\/10.1101\/cshperspect.a038695","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2657_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018;4:3. https:\/\/doi.org\/10.1038\/s41572-018-0002-y","journal-title":"Nat Rev Dis Primers"},{"key":"2657_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1126\/science.adw3278","volume":"387","author":"JL Goodman","year":"2025","unstructured":"Goodman JL, Baylor NW, Katz R, et al. Prepare now for a potential H5N1 pandemic. Science. 2025;387:1047\u20131047. https:\/\/doi.org\/10.1126\/science.adw3278","journal-title":"Science"},{"key":"2657_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41586-024-08054-z","volume":"637","author":"TP Peacock","year":"2025","unstructured":"Peacock TP, Moncla L, Dudas G, et al. The global H5N1 influenza panzootic in mammals. Nature. 2025;637:304\u201313. https:\/\/doi.org\/10.1038\/s41586-024-08054-z","journal-title":"Nature"},{"key":"2657_CR6","unstructured":"CDC. H5 Bird Flu: Current Situation. Avian Influenza (Bird Flu) 2025. https:\/\/www.cdc.gov\/bird-flu\/situation-summary\/index.html (accessed July 4, 2025)."},{"key":"2657_CR7","doi-asserted-by":"publisher","first-page":"2336357","DOI":"10.1080\/21645515.2024.2336357","volume":"20","author":"CA Russell","year":"2024","unstructured":"Russell CA, Fouchier RAM, Ghaswalla P, et al. Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines. Hum Vaccines Immunotherapeutics. 2024;20:2336357. https:\/\/doi.org\/10.1080\/21645515.2024.2336357","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"2657_CR8","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/2211-5463.13416","volume":"12","author":"CJ Caceres","year":"2022","unstructured":"Caceres CJ, Seibert B, Cargnin Faccin F, Cardenas-Garcia S, Rajao DS, Perez DR. Influenza antivirals and animal models. FEBS Open Bio. 2022;12:1142\u201365. https:\/\/doi.org\/10.1002\/2211-5463.13416","journal-title":"FEBS Open Bio"},{"key":"2657_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-1-0716-0346-8_7","volume":"2123","author":"E Spackman","year":"2020","unstructured":"Spackman E. A brief introduction to avian influenza virus. Methods Mol Biol. 2020;2123:83\u201392. https:\/\/doi.org\/10.1007\/978-1-0716-0346-8_7","journal-title":"Methods Mol Biol"},{"key":"2657_CR10","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3390\/ijms18081650","volume":"18","author":"W Shao","year":"2017","unstructured":"Shao W, Li X, Goraya MU, Wang S, Chen J-L. Evolution of influenza A virus by mutation and re-assortment. Int J Mol Sci. 2017;18:1650. https:\/\/doi.org\/10.3390\/ijms18081650","journal-title":"Int J Mol Sci"},{"key":"2657_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/irv.12046","volume":"7","author":"MG Ison","year":"2013","unstructured":"Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses. 2013;7:7\u201313. https:\/\/doi.org\/10.1111\/irv.12046","journal-title":"Influenza Other Respir Viruses"},{"key":"2657_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/ph15010028","volume":"15","author":"F Dufrasne","year":"2021","unstructured":"Dufrasne F. Baloxavir marboxil: an original new drug against influenza. Pharmaceuticals (Basel). 2021;15:28. https:\/\/doi.org\/10.3390\/ph15010028","journal-title":"Pharmaceuticals (Basel)"},{"key":"2657_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","volume":"39","author":"T Lampejo","year":"2020","unstructured":"Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis. 2020;39:1201\u20138. https:\/\/doi.org\/10.1007\/s10096-020-03840-9","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2657_CR14","doi-asserted-by":"publisher","first-page":"e00040","DOI":"10.1128\/cmr.00040-22","volume":"36","author":"R Kumari","year":"2023","unstructured":"Kumari R, Sharma SD, Kumar A, et al. Antiviral approaches against influenza virus. Clin Microbiol Rev. 2023;36:e00040\u201322. https:\/\/doi.org\/10.1128\/cmr.00040-22","journal-title":"Clin Microbiol Rev"},{"key":"2657_CR15","unstructured":"FDA. Influenza (Flu) Antiviral Drugs and Related Information. 2024. https:\/\/www.fda.gov\/drugs\/information-drug-class\/influenza-flu-antiviral-drugs-and-related-information (accessed 07 June 2025)."},{"key":"2657_CR16","unstructured":"CDC. Highly Pathogenic Avian Influenza A(H5N1.) Virus: Interim Recommendations for Prevention, Monitoring, and Public Health Investigations. Avian Influenza (Bird Flu) 2025. https:\/\/www.cdc.gov\/bird-flu\/prevention\/hpai-interim-recommendations.html (accessed June 9, 2025)."},{"key":"2657_CR17","doi-asserted-by":"publisher","first-page":"105499","DOI":"10.1016\/j.antiviral.2022.105499","volume":"210","author":"JC Jones","year":"2023","unstructured":"Jones JC, Yen H-L, Adams P, Armstrong K, Govorkova EA. Influenza antivirals and their role in pandemic preparedness. Antiviral Res. 2023;210:105499. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105499","journal-title":"Antiviral Res"},{"key":"2657_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jinf.2023.01.004","volume":"86","author":"M Reacher","year":"2023","unstructured":"Reacher M, Warne B, Verlander NQ, et al. Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons. J Infect. 2023;86:256\u2013308. https:\/\/doi.org\/10.1016\/j.jinf.2023.01.004","journal-title":"J Infect"},{"key":"2657_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.tips.2007.04.005","volume":"28","author":"E De Clercq","year":"2007","unstructured":"De Clercq E, Neyts J. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharmacol Sci. 2007;28:280\u20135. https:\/\/doi.org\/10.1016\/j.tips.2007.04.005","journal-title":"Trends Pharmacol Sci"},{"key":"2657_CR20","unstructured":"Dectova, European Medicines Agency (EMA). 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dectova (accessed June 9, 2025)."},{"key":"2657_CR21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1517\/14656566.2015.1066336","volume":"16","author":"MM McLaughlin","year":"2015","unstructured":"McLaughlin MM, Skoglund EW, Ison MG. Peramivir: an intravenous neuraminidase inhibitor. Expert Opin Pharmacother. 2015;16:1889\u2013900. https:\/\/doi.org\/10.1517\/14656566.2015.1066336","journal-title":"Expert Opin Pharmacother"},{"key":"2657_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10156-011-0288-0","volume":"17","author":"N Sugaya","year":"2011","unstructured":"Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother. 2011;17:595\u2013601. https:\/\/doi.org\/10.1007\/s10156-011-0288-0","journal-title":"J Infect Chemother"},{"key":"2657_CR23","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/infdis\/jiad418","volume":"229","author":"K Andreev","year":"2023","unstructured":"Andreev K, Jones JC, Seiler P, et al. Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses circulating globally in 2022\u20132023. J Infect Dis. 2023;229:1830\u20135. https:\/\/doi.org\/10.1093\/infdis\/jiad418","journal-title":"J Infect Dis"},{"key":"2657_CR24","doi-asserted-by":"publisher","first-page":"105959","DOI":"10.1016\/j.antiviral.2024.105959","volume":"229","author":"K Andreev","year":"2024","unstructured":"Andreev K, Jones JC, Seiler P, Kandeil A, Webby RJ, Govorkova EA. Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors. Antiviral Res. 2024;229:105959. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105959","journal-title":"Antiviral Res"},{"key":"2657_CR25","doi-asserted-by":"publisher","first-page":"105679","DOI":"10.1016\/j.antiviral.2023.105679","volume":"217","author":"HT Nguyen","year":"2023","unstructured":"Nguyen HT, Chesnokov A, De La Cruz J, et al. Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022. Antiviral Res. 2023;217:105679. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105679","journal-title":"Antiviral Res"},{"key":"2657_CR26","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3201\/eid3104.241820","volume":"31","author":"PNQ Pascua","year":"2025","unstructured":"Pascua PNQ, Chesnokov A, Nguyen HT, et al. Antiviral susceptibility of influenza A(H5N1) clade 2.3.2.1c and 2.3.4.4b viruses from humans, 2023\u20132024. Emerg Infect Dis. 2025;31:751\u201360. https:\/\/doi.org\/10.3201\/eid3104.241820","journal-title":"Emerg Infect Dis"},{"key":"2657_CR27","unstructured":"CDC. Interim Guidance on the Use of Antiviral Medications for Treatment of Human Infections with Novel Influenza A Viruses Associated with Severe Human Disease. Avian Influenza (Bird Flu) 2025. https:\/\/www.cdc.gov\/bird-flu\/hcp\/novel-av-treatment-guidance\/index.html (accessed July 3, 2025)."},{"key":"2657_CR28","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1086\/656316","volume":"202","author":"W Adisasmito","year":"2010","unstructured":"Adisasmito W, Chan PKS, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis. 2010;202:1154\u201360. https:\/\/doi.org\/10.1086\/656316","journal-title":"J Infect Dis"},{"key":"2657_CR29","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/infdis\/jis509","volume":"206","author":"PKS Chan","year":"2012","unstructured":"Chan PKS, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis. 2012;206:1359\u201366. https:\/\/doi.org\/10.1093\/infdis\/jis509","journal-title":"J Infect Dis"},{"key":"2657_CR30","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/S0140-6736(08)60627-3","volume":"371","author":"A Gambotto","year":"2008","unstructured":"Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet. 2008;371:1464\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(08)60627-3","journal-title":"Lancet"},{"key":"2657_CR31","unstructured":"Flint S, Jane et al. Principles of Virology. 4th edition. Washington, DC: ASM Press, 2015. Print."},{"key":"2657_CR32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","volume":"295","author":"RA Bright","year":"2006","unstructured":"Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005\u20132006 influenza season in the United States. JAMA. 2006;295:891\u20134. https:\/\/doi.org\/10.1001\/jama.295.8.joc60020","journal-title":"JAMA"},{"key":"2657_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.micpath.2015.11.008","volume":"91","author":"A Jacob","year":"2016","unstructured":"Jacob A, Sood R, Chanu KV, et al. Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India. Microb Pathog. 2016;91:35\u201340. https:\/\/doi.org\/10.1016\/j.micpath.2015.11.008","journal-title":"Microb Pathog"},{"key":"2657_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1750-2659.2009.00103.x","volume":"3","author":"V Deyde","year":"2009","unstructured":"Deyde V, Garten R, Sheu T, et al. Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006\u20132008. Influenza Other Respir Viruses. 2009;3:297\u2013314. https:\/\/doi.org\/10.1111\/j.1750-2659.2009.00103.x","journal-title":"Influenza Other Respir Viruses"},{"key":"2657_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","volume":"160","author":"T Noshi","year":"2018","unstructured":"Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109\u201317. https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.008","journal-title":"Antiviral Res"},{"key":"2657_CR36","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41564-025-01961-5","volume":"10","author":"JC Jones","year":"2025","unstructured":"Jones JC, Andreev K, Fabrizio TP, Bowman AS, Govorkova EA, Webby RJ. Baloxavir improves disease outcomes in mice after intranasal or ocular infection with influenza A virus H5N1-contaminated cow\u2019s milk. Nat Microbiol. 2025;10:836\u201340. https:\/\/doi.org\/10.1038\/s41564-025-01961-5","journal-title":"Nat Microbiol"},{"key":"2657_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41586-024-08254-7","volume":"636","author":"C Gu","year":"2024","unstructured":"Gu C, Maemura T, Guan L, et al. A human isolate of bovine H5N1 is transmissible and lethal in animal models. Nature. 2024;636:711\u20138. https:\/\/doi.org\/10.1038\/s41586-024-08254-7","journal-title":"Nature"},{"key":"2657_CR38","doi-asserted-by":"publisher","first-page":"e02209","DOI":"10.1128\/jvi.02209-24","volume":"99","author":"F Krammer","year":"2025","unstructured":"Krammer F, Hermann E, Rasmussen AL. Highly pathogenic avian influenza H5N1: history, current situation, and outlook. J Virol. 2025;99:e02209\u201324. https:\/\/doi.org\/10.1128\/jvi.02209-24","journal-title":"J Virol"},{"key":"2657_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1638\/2023-0103","volume":"55","author":"M Miki","year":"2024","unstructured":"Miki M, Obara RD, Nishimura K, et al. Four-week oral administration of baloxavir marboxil as an anti-influenza virus drug shows no toxicity in chickens. J Zoo Wildl Med. 2024;55:313\u201321. https:\/\/doi.org\/10.1638\/2023-0103","journal-title":"J Zoo Wildl Med"},{"key":"2657_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/v12121407","volume":"12","author":"A Twabela","year":"2020","unstructured":"Twabela A, Okamatsu M, Matsuno K, Isoda N, Sakoda Y. Evaluation of baloxavir marboxil and peramivir for the treatment of high pathogenicity avian influenza in chickens. Viruses. 2020;12:1407. https:\/\/doi.org\/10.3390\/v12121407","journal-title":"Viruses"},{"key":"2657_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","volume":"22","author":"D Kumar","year":"2022","unstructured":"Kumar D, Ison MG, Mira J-P, Welte T, Hwan Ha J, Hui DS, et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. 2022;22:718\u201330. https:\/\/doi.org\/10.1016\/S1473-3099(21)00469-2","journal-title":"Lancet Infect Dis"},{"key":"2657_CR42","unstructured":"Clinicaltrials.gov. Identifier NCT04712539. Available online: https:\/\/clinicaltrials.gov\/study\/NCT04712539 (accessed 22 July 2025)."},{"key":"2657_CR43","unstructured":"Clinicaltrials.gov. Identifier NCT06653569. Available online: https:\/\/clinicaltrials.gov\/study\/NCT06653569 (accessed 22 July 2025)."},{"key":"2657_CR44","unstructured":"Clinicaltrials.gov. Identifier NCT04327791. Available online: https:\/\/clinicaltrials.gov\/study\/NCT04327791 (accessed 22 July 2025)."},{"key":"2657_CR45","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1056\/NEJMc2415890","volume":"392","author":"AN Jassem","year":"2025","unstructured":"Jassem AN, Roberts A, Tyson J, et al. Critical illness in an adolescent with influenza A(H5N1) virus infection. N Engl J Med. 2025;392:927\u20139. https:\/\/doi.org\/10.1056\/NEJMc2415890","journal-title":"N Engl J Med"},{"key":"2657_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","volume":"107","author":"J Blaising","year":"2014","unstructured":"Blaising J, Polyak SJ, P\u00e9cheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84\u201394. https:\/\/doi.org\/10.1016\/j.antiviral.2014.04.006","journal-title":"Antiviral Res"},{"key":"2657_CR47","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1002\/iid3.984","volume":"11","author":"Y Kang","year":"2023","unstructured":"Kang Y, Shi Y, Xu S, Arbidol. The current demand, strategies, and antiviral mechanisms. Immun Inflamm Dis. 2023;11:e984. https:\/\/doi.org\/10.1002\/iid3.984","journal-title":"Immun Inflamm Dis"},{"key":"2657_CR48","first-page":"84","volume":"77","author":"IA Leneva","year":"2005","unstructured":"Leneva IA, Fediakina IT, Gus\u2019kova TA, Glushkov RG. [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]. Ter Arkh. 2005;77:84\u20138.","journal-title":"Ter Arkh"},{"key":"2657_CR49","first-page":"10","volume":"56","author":"SI Loginova","year":"2011","unstructured":"Loginova SI, Borisevich SV, Maksimov VA, et al. Therapeutic efficacy of triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1). Antibiot Khimioter. 2011;56:10\u20132.","journal-title":"Antibiot Khimioter"},{"key":"2657_CR50","doi-asserted-by":"publisher","first-page":"14537","DOI":"10.3390\/ijms232314537","volume":"23","author":"ON Chupakhin","year":"2022","unstructured":"Chupakhin ON, Rusinov VL, Varaksin MV, et al. Triazavirin-A novel effective antiviral drug. Int J Mol Sci. 2022;23:14537. https:\/\/doi.org\/10.3390\/ijms232314537","journal-title":"Int J Mol Sci"},{"key":"2657_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.37489\/0235-2990-2021-66-5-6-58-71","volume":"66","author":"AU Sabitov","year":"2021","unstructured":"Sabitov AU, Kovtun OP, Batskalevich NA, et al. Meta-analysis of randomized clinical trials of riamilovir efficacy in etiotropic therapy of influenza. Antibiot Khimioter = Antibiot Chemother. 2021;66:58\u201371. https:\/\/doi.org\/10.37489\/0235-2990-2021-66-5-6-58-71","journal-title":"Antibiot Khimioter = Antibiot Chemother"},{"key":"2657_CR52","first-page":"18","volume":"52","author":"SI Loginova","year":"2007","unstructured":"Loginova SI, Borisevich SV, Maksimov VA, et al. Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture. Antibiot Khimioter. 2007;52:18\u201320.","journal-title":"Antibiot Khimioter"},{"key":"2657_CR53","first-page":"25","volume":"55","author":"SI Loginova","year":"2010","unstructured":"Loginova SI, Borisevich SV, Maksimov VA, et al. Triazavirin prophylactic efficacy against influenza virus A (H5N1). Antibiot Khimioter. 2010;55:25\u20138.","journal-title":"Antibiot Khimioter"},{"key":"2657_CR54","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3390\/ph4121518","volume":"4","author":"VV Zarubaev","year":"2011","unstructured":"Zarubaev VV, Garshinina AV, Kalinina NA, et al. Activity of ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic acid) against human respiratory viruses in in vivo experiments. Pharmaceuticals (Basel). 2011;4:1518\u201334. https:\/\/doi.org\/10.3390\/ph4121518","journal-title":"Pharmaceuticals (Basel)"},{"key":"2657_CR55","first-page":"10","volume":"55","author":"SI Loginova","year":"2010","unstructured":"Loginova SI, Borisevich SV, Shkliaeva OM, Maksimov VA, Bondarev VP, Nebol\u2019sin VE. Prophylactic and therapeutic efficacies of Ingavirin, a novel Russian chemotherapeutic, with respect to influenza pathogen A (H5N1). Antibiot Khimioter. 2010;55:10\u20132.","journal-title":"Antibiot Khimioter"},{"key":"2657_CR56","unstructured":"Shishkina LN, Nebol\u2019sin VE, Kabanov AS et al. In vitro and in vivo efficacy of ingavirin against strains of pandemic influenza virus A(H1N1\/09)v. Zh Mikrobiol Epidemiol Immunobiol. 2011:93\u20136."},{"key":"2657_CR57","doi-asserted-by":"publisher","unstructured":"te Velthuis AJW, Zubkova TG, Shaw M, et al. Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity. Antimicrob Agents Chemother. 2021;65. https:\/\/doi.org\/10.1128\/aac.02605-20","DOI":"10.1128\/aac.02605-20"},{"key":"2657_CR58","doi-asserted-by":"publisher","first-page":"204020661881141","DOI":"10.1177\/2040206618811416","volume":"26","author":"D Boltz","year":"2018","unstructured":"Boltz D, Peng X, Muzzio M, Dash P, Thomas PG, Margitich V. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antivir Chem Chemother. 2018;26:2040206618811416. https:\/\/doi.org\/10.1177\/2040206618811416","journal-title":"Antivir Chem Chemother"},{"key":"2657_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3851\/IMP1688","volume":"21","author":"M Yamashita","year":"2010","unstructured":"Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antivir Chem Chemother. 2010;21:71\u201384. https:\/\/doi.org\/10.3851\/IMP1688","journal-title":"Antivir Chem Chemother"},{"key":"2657_CR60","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jiac.2019.02.023","volume":"25","author":"T Tomozawa","year":"2019","unstructured":"Tomozawa T, Hoshino K, Yamashita M, Kubo S. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus. J Infect Chemother. 2019;25:584\u20138. https:\/\/doi.org\/10.1016\/j.jiac.2019.02.023","journal-title":"J Infect Chemother"},{"key":"2657_CR61","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijantimicag.2012.06.017","volume":"40","author":"S Kashiwagi","year":"2012","unstructured":"Kashiwagi S, Yoshida S, Yamaguchi H, et al. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance. Int J Antimicrob Agents. 2012;40:381\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.06.017","journal-title":"Int J Antimicrob Agents"},{"key":"2657_CR62","doi-asserted-by":"publisher","first-page":"e1000786","DOI":"10.1371\/journal.ppat.1000786","volume":"6","author":"M Kiso","year":"2010","unstructured":"Kiso M, Kubo S, Ozawa M, et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 2010;6:e1000786. https:\/\/doi.org\/10.1371\/journal.ppat.1000786","journal-title":"PLoS Pathog"},{"key":"2657_CR63","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107512","journal-title":"Pharmacol Ther"},{"key":"2657_CR64","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/pharmaceutics15061732","volume":"15","author":"B Ganter","year":"2023","unstructured":"Ganter B, Zickler M, Huchting J, et al. T-705-derived prodrugs show high antiviral efficacies against a broad range of influenza A viruses with synergistic effects when combined with oseltamivir. Pharmaceutics. 2023;15:1732. https:\/\/doi.org\/10.3390\/pharmaceutics15061732","journal-title":"Pharmaceutics"},{"key":"2657_CR65","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.01051-06","volume":"51","author":"RW Sidwell","year":"2007","unstructured":"Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007;51:845\u201351. https:\/\/doi.org\/10.1128\/AAC.01051-06","journal-title":"Antimicrob Agents Chemother"},{"key":"2657_CR66","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1073\/pnas.0909603107","volume":"107","author":"M Kiso","year":"2010","unstructured":"Kiso M, Takahashi K, Sakai-Tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A. 2010;107:882\u20137. https:\/\/doi.org\/10.1073\/pnas.0909603107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2657_CR67","doi-asserted-by":"publisher","first-page":"26742","DOI":"10.1038\/srep26742","volume":"6","author":"BM Marathe","year":"2016","unstructured":"Marathe BM, Wong S-S, Vogel P, et al. Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice. Sci Rep. 2016;6:26742. https:\/\/doi.org\/10.1038\/srep26742","journal-title":"Sci Rep"},{"key":"2657_CR68","doi-asserted-by":"publisher","first-page":"105035","DOI":"10.1016\/j.antiviral.2021.105035","volume":"188","author":"MC Patel","year":"2021","unstructured":"Patel MC, Chesnokov A, Jones J, et al. Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir. Antiviral Res. 2021;188:105035. https:\/\/doi.org\/10.1016\/j.antiviral.2021.105035","journal-title":"Antiviral Res"},{"key":"2657_CR69","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1021\/jm5007275","volume":"57","author":"MP Clark","year":"2014","unstructured":"Clark MP, Ledeboer MW, Davies I, et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014;57:6668\u201378. https:\/\/doi.org\/10.1021\/jm5007275","journal-title":"J Med Chem"},{"key":"2657_CR70","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/AAC.04623-14","volume":"59","author":"RA Byrn","year":"2015","unstructured":"Byrn RA, Jones SM, Bennett HB, et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 2015;59:1569\u201382. https:\/\/doi.org\/10.1128\/AAC.04623-14","journal-title":"Antimicrob Agents Chemother"},{"key":"2657_CR71","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1093\/infdis\/jiae408","volume":"231","author":"L Leopold","year":"2025","unstructured":"Leopold L, Vingerhoets J, Deleu S, et al. Efficacy and safety of pimodivir combined with standard of care in hospitalized and nonhospitalized high-risk adolescents and adults with influenza A infection. J Infect Dis. 2025;231:e132\u201343. https:\/\/doi.org\/10.1093\/infdis\/jiae408","journal-title":"J Infect Dis"},{"key":"2657_CR72","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/v14030612","volume":"14","author":"RA Tripp","year":"2022","unstructured":"Tripp RA, Martin DE. Repurposing probenecid to inhibit SARS-CoV-2, influenza virus, and respiratory syncytial virus (RSV) replication. Viruses. 2022;14:612. https:\/\/doi.org\/10.3390\/v14030612","journal-title":"Viruses"},{"key":"2657_CR73","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1128\/AAC.01532-12","volume":"57","author":"O Perwitasari","year":"2013","unstructured":"Perwitasari O, Yan X, Johnson S, et al. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother. 2013;57:475\u201383. https:\/\/doi.org\/10.1128\/AAC.01532-12","journal-title":"Antimicrob Agents Chemother"},{"key":"2657_CR74","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/v15122366","volume":"15","author":"J Murray","year":"2023","unstructured":"Murray J, Martin DE, Sancilio FD, Tripp RA. Antiviral activity of probenecid and oseltamivir on influenza virus replication. Viruses. 2023;15:2366. https:\/\/doi.org\/10.3390\/v15122366","journal-title":"Viruses"},{"key":"2657_CR75","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/v17030335","volume":"17","author":"J Murray","year":"2025","unstructured":"Murray J, Nogales A, Martinez-Sobrido L, Martin DE, Sancilio FD, Tripp RA. Evaluating probenecid or oseltamivir inhibition of influenza A virus replication through plaque assay or fluorescent focus assay using non-structural protein 1-H1N1 venus reporter virus. Viruses. 2025;17:335. https:\/\/doi.org\/10.3390\/v17030335","journal-title":"Viruses"},{"key":"2657_CR76","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/v16010152","volume":"16","author":"J Murray","year":"2024","unstructured":"Murray J, Martin DE, Hosking S, Orr-Burks N, Hogan RJ, Tripp RA. Probenecid inhibits influenza A(H5N1) and A(H7N9) viruses in vitro and in mice. Viruses. 2024;16:152. https:\/\/doi.org\/10.3390\/v16010152","journal-title":"Viruses"},{"key":"2657_CR77","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/toxsci\/kfr109","volume":"122","author":"JL Larson","year":"2011","unstructured":"Larson JL, Kang S-K, Choi BI, et al. A safety evaluation of DAS181, a sialidase fusion protein, in rodents. Toxicol Sci. 2011;122:567\u201378. https:\/\/doi.org\/10.1093\/toxsci\/kfr109","journal-title":"Toxicol Sci"},{"key":"2657_CR78","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.antiviral.2015.09.008","volume":"123","author":"JM Zenilman","year":"2015","unstructured":"Zenilman JM, Fuchs EJ, Hendrix CW, et al. Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults. Antiviral Res. 2015;123:114\u20139. https:\/\/doi.org\/10.1016\/j.antiviral.2015.09.008","journal-title":"Antiviral Res"},{"key":"2657_CR79","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/infdis\/jiu105","volume":"210","author":"H Marjuki","year":"2014","unstructured":"Marjuki H, Mishin VP, Chesnokov AP, et al. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis. 2014;210:435\u201340. https:\/\/doi.org\/10.1093\/infdis\/jiu105","journal-title":"J Infect Dis"},{"key":"2657_CR80","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1128\/AAC.00389-09","volume":"53","author":"RWY Chan","year":"2009","unstructured":"Chan RWY, Chan MCW, Wong ACN, et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother. 2009;53:3935\u201341. https:\/\/doi.org\/10.1128\/AAC.00389-09","journal-title":"Antimicrob Agents Chemother"},{"key":"2657_CR81","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1086\/522609","volume":"196","author":"JA Belser","year":"2007","unstructured":"Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis. 2007;196:1493\u20139. https:\/\/doi.org\/10.1086\/522609","journal-title":"J Infect Dis"},{"key":"2657_CR82","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/nbt.1638","volume":"28","author":"RY Kao","year":"2010","unstructured":"Kao RY, Yang D, Lau L-S, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28:600\u20135. https:\/\/doi.org\/10.1038\/nbt.1638","journal-title":"Nat Biotechnol"},{"key":"2657_CR83","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1021\/jm2013503","volume":"55","author":"H Cheng","year":"2012","unstructured":"Cheng H, Wan J, Lin M-I, et al. Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein. J Med Chem. 2012;55:2144\u201353. https:\/\/doi.org\/10.1021\/jm2013503","journal-title":"J Med Chem"},{"key":"2657_CR84","doi-asserted-by":"publisher","first-page":"e1011342","DOI":"10.1371\/journal.ppat.1011342","volume":"19","author":"CM Lieber","year":"2023","unstructured":"Lieber CM, Aggarwal M, Yoon J-J, et al. 4\u2019-fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses. PLoS Pathog. 2023;19:e1011342. https:\/\/doi.org\/10.1371\/journal.ppat.1011342","journal-title":"PLoS Pathog"},{"key":"2657_CR85","doi-asserted-by":"publisher","first-page":"e1011993","DOI":"10.1371\/journal.ppat.1011993","volume":"20","author":"CM Lieber","year":"2024","unstructured":"Lieber CM, Kang H-J, Aggarwal M, et al. Influenza A virus resistance to 4\u2019-fluorouridine coincides with viral attenuation in vitro and in vivo. PLoS Pathog. 2024;20:e1011993. https:\/\/doi.org\/10.1371\/journal.ppat.1011993","journal-title":"PLoS Pathog"},{"key":"2657_CR86","doi-asserted-by":"publisher","first-page":"106046","DOI":"10.1016\/j.antiviral.2024.106046","volume":"233","author":"L Schrell","year":"2025","unstructured":"Schrell L, Fuchs HL, Dickmanns A, et al. Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4\u2032-fluorouridine. Antiviral Res. 2025;233:106046. https:\/\/doi.org\/10.1016\/j.antiviral.2024.106046","journal-title":"Antiviral Res"},{"key":"2657_CR87","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1038\/s41401-024-01331-7","volume":"45","author":"Y-Y Li","year":"2024","unstructured":"Li Y-Y, Liang G-D, Chen Z-X, et al. A small molecule compound targeting hemagglutinin inhibits influenza A virus and exhibits broad-spectrum antiviral activity. Acta Pharmacol Sin. 2024;45:2380\u201393. https:\/\/doi.org\/10.1038\/s41401-024-01331-7","journal-title":"Acta Pharmacol Sin"},{"key":"2657_CR88","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1038\/s41598-017-04777-4","volume":"7","author":"H-J Moon","year":"2017","unstructured":"Moon H-J, Nikapitiya C, Lee H-C, et al. Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses. Sci Rep. 2017;7:4875. https:\/\/doi.org\/10.1038\/s41598-017-04777-4","journal-title":"Sci Rep"},{"key":"2657_CR89","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/s41467-021-22964-w","volume":"12","author":"M Saito","year":"2021","unstructured":"Saito M, Itoh Y, Yasui F, et al. Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models. Nat Commun. 2021;12:2654. https:\/\/doi.org\/10.1038\/s41467-021-22964-w","journal-title":"Nat Commun"},{"key":"2657_CR90","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/irv.12446","volume":"11","author":"P Koszalka","year":"2017","unstructured":"Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respir Viruses. 2017;11:240\u20136. https:\/\/doi.org\/10.1111\/irv.12446","journal-title":"Influenza Other Respir Viruses"},{"key":"2657_CR91","doi-asserted-by":"publisher","first-page":"e00949","DOI":"10.1128\/JVI.00949-18","volume":"92","author":"R Nachbagauer","year":"2018","unstructured":"Nachbagauer R, Shore D, Yang H, et al. Broadly reactive human monoclonal antibodies elicited following pandemic H1N1 influenza virus exposure protect mice against highly pathogenic H5N1 challenge. J Virol. 2018;92:e00949\u201318. https:\/\/doi.org\/10.1128\/JVI.00949-18","journal-title":"J Virol"},{"key":"2657_CR92","doi-asserted-by":"publisher","first-page":"e9106","DOI":"10.1371\/journal.pone.0009106","volume":"5","author":"RHE Friesen","year":"2010","unstructured":"Friesen RHE, Koudstaal W, Koldijk MH, et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS ONE. 2010;5:e9106. https:\/\/doi.org\/10.1371\/journal.pone.0009106","journal-title":"PLoS ONE"},{"key":"2657_CR93","doi-asserted-by":"publisher","first-page":"611958","DOI":"10.3389\/fmicb.2021.611958","volume":"12","author":"H Hamza","year":"2021","unstructured":"Hamza H, Shehata MM, Mostafa A, Pleschka S, Planz O. Improved in vitro efficacy of baloxavir marboxil against influenza A virus infection by combination treatment with the MEK inhibitor ATR-002. Front Microbiol. 2021;12:611958. https:\/\/doi.org\/10.3389\/fmicb.2021.611958","journal-title":"Front Microbiol"},{"key":"2657_CR94","doi-asserted-by":"publisher","first-page":"2471022","DOI":"10.1080\/22221751.2025.2471022","volume":"14","author":"A Schreiber","year":"2025","unstructured":"Schreiber A, Oberberg N, Ambrosy B, et al. Influenza H5Nx viruses are susceptible to MEK1\/2 inhibition by zapnometinib. Emerg Microbes Infect. 2025;14:2471022. https:\/\/doi.org\/10.1080\/22221751.2025.2471022","journal-title":"Emerg Microbes Infect"},{"key":"2657_CR95","doi-asserted-by":"publisher","first-page":"1360698","DOI":"10.3389\/fimmu.2024.1360698","volume":"15","author":"J Koch-Heier","year":"2024","unstructured":"Koch-Heier J, Vogel AB, F\u00fcll Y, et al. MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection. Front Immunol. 2024;15:1360698. https:\/\/doi.org\/10.3389\/fimmu.2024.1360698","journal-title":"Front Immunol"},{"key":"2657_CR96","doi-asserted-by":"publisher","first-page":"1050193","DOI":"10.3389\/fphar.2022.1050193","volume":"13","author":"Y F\u00fcll","year":"2022","unstructured":"F\u00fcll Y, Wallasch C, Hilton A, Planz O. Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats. Front Pharmacol. 2022;13:1050193. https:\/\/doi.org\/10.3389\/fphar.2022.1050193","journal-title":"Front Pharmacol"},{"key":"2657_CR97","doi-asserted-by":"publisher","first-page":"105701","DOI":"10.1016\/j.antiviral.2023.105701","volume":"217","author":"AA Ivashchenko","year":"2023","unstructured":"Ivashchenko AA, Jones JC, Shkil DO, et al. Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses. Antiviral Res. 2023;217:105701. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105701","journal-title":"Antiviral Res"},{"key":"2657_CR98","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1093\/jac\/dku074","volume":"69","author":"AV Ivachtchenko","year":"2014","unstructured":"Ivachtchenko AV, Ivanenkov YA, Mitkin OD, et al. Novel oral anti-influenza drug candidate AV5080. J Antimicrob Chemother. 2014;69:1892\u2013902. https:\/\/doi.org\/10.1093\/jac\/dku074","journal-title":"J Antimicrob Chemother"},{"key":"2657_CR99","unstructured":"ChinaDaily.com. China approves novel homegrown flu drug. https:\/\/www.chinadaily.com.cn\/a\/202506\/11\/WS6848d798a310a04af22c5849.html (accessed July 22, 2025)."},{"key":"2657_CR100","unstructured":"ChinaDaily.com. Domestic single-dose flu drug approved. https:\/\/www.chinadaily.com.cn\/a\/202507\/19\/WS687aea94a310ad07b5d90c9a.html (accessed July 22, 2025)."},{"key":"2657_CR101","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1473-3099(23)00743-0","volume":"24","author":"Z Yang","year":"2024","unstructured":"Yang Z, Li Z, Zhan Y, et al. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2024;24:535\u201345. https:\/\/doi.org\/10.1016\/S1473-3099(23)00743-0","journal-title":"Lancet Infect Dis"},{"key":"2657_CR102","doi-asserted-by":"publisher","first-page":"e0172924","DOI":"10.1128\/aac.01729-24","volume":"69","author":"Y Pang","year":"2025","unstructured":"Pang Y, Li H, Chen X, et al. A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects. Antimicrob Agents Chemother. 2025;69:e0172924. https:\/\/doi.org\/10.1128\/aac.01729-24","journal-title":"Antimicrob Agents Chemother"},{"key":"2657_CR103","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S2213-2600(25)00046-3","volume":"13","author":"Z Yang","year":"2025","unstructured":"Yang Z, Zhan Y, Li Z, Lin Z, Fang Z, Li H, et al. Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in china: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial. Lancet Respiratory Med. 2025;13:597\u2013610. https:\/\/doi.org\/10.1016\/S2213-2600(25)00046-3","journal-title":"Lancet Respiratory Med"},{"key":"2657_CR104","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41591-024-03419-3","volume":"31","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang H, Zhang Y, et al. Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2025;31:639\u201346. https:\/\/doi.org\/10.1038\/s41591-024-03419-3","journal-title":"Nat Med"},{"key":"2657_CR105","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cmi.2025.01.025","volume":"31","author":"Y Wang","year":"2025","unstructured":"Wang Y, Wang H, Liu D, et al. Efficacy and safety of single-dose suraxavir marboxil tablet in the treatment of acute uncomplicated influenza in adults: a multi-centre, randomized, double-blind, placebo-controlled phase 2 clinical trial. Clin Microbiol Infect. 2025;31:861\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2025.01.025","journal-title":"Clin Microbiol Infect"},{"key":"2657_CR106","doi-asserted-by":"publisher","first-page":"107381","DOI":"10.1016\/j.ijantimicag.2024.107381","volume":"65","author":"J Wu","year":"2025","unstructured":"Wu J, Wei Q, Jin Y, et al. Safety, tolerability, and pharmacokinetics of a novel anti-influenza agent ZX-7101A tablets in healthy Chinese participants: a first-in-human phase I clinical study. Int J Antimicrob Agents. 2025;65:107381. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107381","journal-title":"Int J Antimicrob Agents"},{"key":"2657_CR107","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cmi.2024.10.020","volume":"31","author":"H Wang","year":"2025","unstructured":"Wang H, Wang G, Gao Y, et al. Efficacy and safety of ZX-7101A, an inhibitor of influenza cap-dependent endonuclease, in adults with uncomplicated influenza: a randomized, double-blind, placebo-controlled phase 2\/3 trial. Clin Microbiol Infect. 2025;31:274\u201381. https:\/\/doi.org\/10.1016\/j.cmi.2024.10.020","journal-title":"Clin Microbiol Infect"},{"key":"2657_CR108","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41564-025-01955-3","volume":"10","author":"S D\u00f6hrmann","year":"2025","unstructured":"D\u00f6hrmann S, Levin J, Cole JN, Borchardt A, Amundson K, Almaguer A, et al. Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice. Nat Microbiol. 2025;10:912\u201326. https:\/\/doi.org\/10.1038\/s41564-025-01955-3","journal-title":"Nat Microbiol"},{"key":"2657_CR109","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.dmd.2025.100103","volume":"53","author":"A Laenen","year":"2025","unstructured":"Laenen A, Flanagan S, Hough G, Snoeys J, Cuyckens F, Mannens G, et al. Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of 14\u00a0C-CD388 in the rat. Drug Metab Dispos. 2025;53:100103. https:\/\/doi.org\/10.1016\/j.dmd.2025.100103","journal-title":"Drug Metab Dispos"},{"key":"2657_CR110","unstructured":"Clinicaltrials.gov. Identifier NCT05285137. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05285137 (accessed 22 July 2025)."},{"key":"2657_CR111","unstructured":"Clinicaltrials.gov. Identifier NCT05619536. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05619536 (accessed 22 July 2025)."},{"key":"2657_CR112","unstructured":"Clinicaltrials.gov. Identifier NCT05523089. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05523089 (accessed 22 July 2025)."},{"key":"2657_CR113","unstructured":"Clinicaltrials.gov. Identifier NCT06609460. Available online: https:\/\/clinicaltrials.gov\/study\/NCT06609460 (accessed 22 July 2025)."},{"key":"2657_CR114","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"J-F Rossignol","year":"2014","unstructured":"Rossignol J-F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94\u2013103. https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.014","journal-title":"Antiviral Res"},{"key":"2657_CR115","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.antiviral.2018.01.002","volume":"150","author":"DS Hui","year":"2018","unstructured":"Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res. 2018;150:202\u201316. https:\/\/doi.org\/10.1016\/j.antiviral.2018.01.002","journal-title":"Antiviral Res"},{"key":"2657_CR116","doi-asserted-by":"publisher","first-page":"1272466","DOI":"10.3389\/fphar.2023.1272466","volume":"14","author":"S-M Xu","year":"2023","unstructured":"Xu S-M, Chang L-W, Tsai C-Y, et al. Safety, tolerability, and pharmacokinetics of TG-1000, a new molecular entity against influenza virus: first-in-human study. Front Pharmacol. 2023;14:1272466. https:\/\/doi.org\/10.3389\/fphar.2023.1272466","journal-title":"Front Pharmacol"},{"key":"2657_CR117","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00018-025-05611-1","volume":"82","author":"A Bonomini","year":"2025","unstructured":"Bonomini A, Mercorelli B, Loregian A. Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches. Cell Mol Life Sci. 2025;82:75. https:\/\/doi.org\/10.1007\/s00018-025-05611-1","journal-title":"Cell Mol Life Sci"},{"key":"2657_CR118","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3851\/IMP3244","volume":"23","author":"TN Kakuda","year":"2018","unstructured":"Kakuda TN, Yogaratnam J, Rito J, Boyce M, Mitchell T, Gupta K, et al. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults. Antivir Ther. 2018;23:555\u201366. https:\/\/doi.org\/10.3851\/IMP3244","journal-title":"Antivir Ther"},{"key":"2657_CR119","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/infdis\/jiy410","volume":"219","author":"J Yogaratnam","year":"2019","unstructured":"Yogaratnam J, Rito J, Kakuda TN, et al. Antiviral activity, safety, and pharmacokinetics of AL-794, a novel oral influenza endonuclease inhibitor: results of an influenza human challenge study. J Infect Dis. 2019;219:177\u201385. https:\/\/doi.org\/10.1093\/infdis\/jiy410","journal-title":"J Infect Dis"},{"key":"2657_CR120","doi-asserted-by":"publisher","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","volume":"169","author":"EJ Mifsud","year":"2019","unstructured":"Mifsud EJ, Hayden FG, Hurt AC. Antivirals targeting the polymerase complex of influenza viruses. Antiviral Res. 2019;169:104545. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104545","journal-title":"Antiviral Res"},{"key":"2657_CR121","doi-asserted-by":"publisher","first-page":"e29372","DOI":"10.1002\/jmv.29372","volume":"96","author":"J Li","year":"2024","unstructured":"Li J, Takeda M, Imahatakenaka M, Ikeda M. Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus. J Med Virol. 2024;96:e29372. https:\/\/doi.org\/10.1002\/jmv.29372","journal-title":"J Med Virol"},{"key":"2657_CR122","doi-asserted-by":"publisher","first-page":"eaar6221","DOI":"10.1126\/science.aar6221","volume":"363","author":"MJP van Dongen","year":"2019","unstructured":"van Dongen MJP, Kadam RU, Juraszek J, et al. A small-molecule fusion inhibitor of influenza virus is orally active in mice. Science. 2019;363:eaar6221. https:\/\/doi.org\/10.1126\/science.aar6221","journal-title":"Science"},{"key":"2657_CR123","doi-asserted-by":"publisher","unstructured":"Yao Y, Kadam RU, Lee C-CD et al. An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. Proceedings of the National Academy of Sciences. 2020;117:18431\u20138. https:\/\/doi.org\/10.1073\/pnas.2006893117","DOI":"10.1073\/pnas.2006893117"},{"key":"2657_CR124","doi-asserted-by":"publisher","first-page":"107522","DOI":"10.1016\/j.ijantimicag.2025.107522","volume":"66","author":"C Anastassopoulou","year":"2025","unstructured":"Anastassopoulou C, Panagiotopoulos A-P, Siafakas N, Tsakris A. The potential of RNA-binding proteins as host-targeting antivirals against RNA viruses. Int J Antimicrob Agents. 2025;66:107522. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107522","journal-title":"Int J Antimicrob Agents"},{"key":"2657_CR125","doi-asserted-by":"publisher","first-page":"e00224","DOI":"10.1128\/CMR.00224-20","volume":"34","author":"EC Holmes","year":"2021","unstructured":"Holmes EC, Hurt AC, Dobbie Z, Clinch B, Oxford JS, Piedra PA. Understanding the impact of resistance to influenza antivirals. Clin Microbiol Rev. 2021;34:e00224\u201320. https:\/\/doi.org\/10.1128\/CMR.00224-20","journal-title":"Clin Microbiol Rev"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02657-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:04:32Z","timestamp":1779361472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02657-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":125,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2657"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02657-y","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}